Clinical Trial Update: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated gilteritinib alone or with azacitidine versus azacitidine alone in adults with newly diagnosed acute myeloid leukemia carrying an F…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3 Mutation

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Gilteritinib (ASP2215) (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation | Phase 3 | Status: COMPLETED | Results posted: 2025-09-12